| abstract |
The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection. In particular the application is directed to a solid dosage form comprising ABT-450 (paritaprevir), ABT-267 (ombitasvir), ritonavir and ABT-333 (dasabuvir) for the treatment of infections by hepatitis C virus (HCV). As an exemplary formulation a bilayer tablet is disclosed. |